Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients.

Details

Serval ID
serval:BIB_93DD589D4F0E
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Gut barrier and microbiota changes with glycine and branched-chain amino acid supplementation in chronic haemodialysis patients.
Journal
Journal of cachexia, sarcopenia and muscle
Author(s)
Genton L., Pruijm M., Teta D., Bassi I., Cani P.D., Gaïa N., Herrmann F.R., Marangon N., Mareschal J., Muccioli G.G., Stoermann C., Suriano F., Wurzner-Ghajarzadeh A., Lazarevic V., Schrenzel J.
ISSN
2190-6009 (Electronic)
ISSN-L
2190-5991
Publication state
Published
Issued date
12/2021
Peer-reviewed
Oui
Volume
12
Number
6
Pages
1527-1539
Language
english
Notes
Publication types: Journal Article ; Multicenter Study ; Randomized Controlled Trial ; Research Support, Non-U.S. Gov't
Publication Status: ppublish
Abstract
We have previously shown that glycine increases fat-free mass in chronic haemodialysis patients with features of malnutrition as compared with branched-chain amino acids (BCAAs). This multicentre randomized double-blind crossover study evaluates the impact of these amino acids on the gut barrier and microbiota.
Haemodialysis patients were included if they had plasma albumin <38 g/L or weight loss >5% of dry body weight, and daily dietary intakes <30 kcal/kg and <1 g protein/kg. They consumed glycine or BCAA (7 g twice daily) for 4 months and underwent a 1 month washout period, before crossover of supplementations. Faecal microbiota (16S rRNA gene sequencing) and immunoglobulin A (IgA), serum levels of cytokines, surrogate markers of intestinal permeability, appetite mediators, and endocannabinoids were obtained at the start and end of each supplementation. Supplementations were compared by multiple mixed linear regression models, adjusted for age, sex, month of supplementation (0 and 4 in each period), and period (Period 1: first 4 months; Period 2: last 4 months). Microbiota comparisons were performed using principal coordinate analysis and permutational multivariate analysis of variance, Shannon diversity index estimate and analysis of composition of microbiomes analysis, and Wilcoxon tests.
We analysed 27 patients compliant to the supplementations. Multiple mixed linear regression models were significant only for interleukin-6 (P = 0.002), glucagon-like peptide 1 (P = 0.028), cholecystokinin (P = 0.021), and peptide YY (P = 0.002), but not for the other outcomes. The significant models did not show any impact of the type of supplementation (P < 0.05 in all models). Principal coordinate analysis and permutational multivariate analysis of variance (P = 0.0001) showed strong microbiota clustering by subject, but no effect of the amino acids. Bacterial alpha diversity and zero-radius operational taxonomic unit richness remained stable, whatever the supplementation. Lacticaseibacillus paracasei (0.030; Q1-Q3 0.008-0.078 vs. 0.004; Q1-Q3 0.001-0.070) and Bifidobacterium dentium (0.0247; Q1-Q3 0.002-0.191 vs. 0.003; Q1-Q3 0.001-0.086) significantly decreased with the BCAA supplementation.
The BCAA and glycine supplementations had no impact on the serum levels of cytokines, appetite mediators, intestinal permeability, endocannabinoids, or faecal IgA. Overall faecal microbiota composition and microbial diversity did not change with the glycine or BCAA supplementation but decreased the abundance of L. paracasei and B. dentium.
Keywords
Amino Acids, Branched-Chain, Cross-Over Studies, Dietary Supplements, Glycine, Humans, Microbiota, RNA, Ribosomal, 16S/genetics, Renal Dialysis, Appetite, Branched-chain amino acid malnutrition, Endocannabinoids, Gut microbiota
Pubmed
Web of science
Open Access
Yes
Create date
24/09/2021 17:22
Last modification date
09/02/2022 7:32
Usage data